oral
corticosteroid
cornerston
manag
acut
moder
sever
asthma
whilst
prevent
inhal
corticosteroid
mainstay
daili
manag
children
asthma
yet
sever
report
recent
shaken
belief
equal
effect
patient
asthma
suggest
instanc
preschool
children
viralinduc
wheez
somewhat
corticosteroidresist
definit
asthma
children
adult
requir
document
airway
obstruct
reversibilityhyperreact
concept
appli
preschoolag
children
young
sick
cooper
standard
spirometri
children
airway
obstruct
document
classic
sign
cough
decreas
air
entri
wheez
symptom
cough
wheez
dyspnoea
expector
accessori
muscl
use
impair
air
exchang
paramet
revers
reflect
improv
follow
bronchodil
andor
corticosteroid
hyperreact
support
deterior
upon
exposur
specif
trigger
children
meet
criteria
diagnos
asthma
first
episod
thu
avoid
unnecessari
delay
treatment
infant
toddler
critic
distinguish
asthma
bronchiol
bronchiol
clinic
defin
first
wheez
ill
child
month
respiratori
syncyti
viru
rsv
frequent
pathogen
although
display
similar
sign
symptom
airway
obstruct
children
bronchiol
nt
fit
definit
asthma
show
paediatr
respiratori
review
reader
abl
examin
evid
support
variat
effect
oral
inhal
corticosteroid
across
paediatr
asthma
phenotyp
highlight
key
determin
may
modul
respons
corticosteroid
review
effect
phenotypespecif
treatment
option
oral
corticosteroid
cornerston
manag
acut
moder
sever
asthma
whilst
prevent
inhal
corticosteroid
mainstay
prevent
manag
children
asthma
yet
variat
magnitud
respons
corticosteroid
observ
increas
evid
preschoolag
children
viralinduc
asthma
may
display
certain
degre
corticosteroid
resist
requir
higher
dose
corticosteroid
overcom
identif
determin
respons
complic
design
issu
includ
heterogen
popul
children
asthma
bronchiol
children
viralinduc
multitrigg
asthma
phenotyp
publish
trial
potenti
key
determin
respons
may
includ
age
trigger
phenotyp
tobacco
smoke
exposur
genotyp
mechanist
pathway
corticoresist
may
origin
geneenviron
interact
lead
noneosinophil
airway
inflamm
clinician
care
confirm
diagnosi
asthma
ascertain
phenotyp
select
appropri
phenotypespecif
therapi
elsevi
ltd
right
reserv
signific
revers
inhal
corticosteroid
except
evidenc
recent
multicentr
bronchiol
trial
report
respons
individu
drug
unexpectantli
signific
respons
combin
highdos
oral
steroid
dexamethason
nebulis
adrenerg
agonist
epinephrin
studi
current
replic
confirm
findng
reduc
risk
misclassif
bronchiol
two
three
wheez
episod
commonli
requir
diagnosi
asthma
children
age
month
less
gener
therapeut
studi
preschool
wheez
often
difficult
interpret
gener
includ
heterogen
wheez
group
inde
inclus
children
bronchiol
asthma
probabl
explain
poor
respons
oral
corticosteroid
studi
includ
infant
toddler
care
attent
popul
studi
thu
critic
interpret
literatur
mani
classif
propos
two
main
phenotyp
consid
viralinduc
asthma
refer
children
exacerb
sole
trigger
viral
respiratori
infect
symptom
episod
phenotyp
pertain
almost
exclus
young
children
age
year
symptom
resolv
age
year
recent
trial
children
viralinduc
asthma
age
year
age
year
evolv
toward
multitrigg
asthma
cours
studi
contrast
children
symptom
trigger
two
factor
eg
viral
infect
weather
activ
allergen
usual
symptom
episod
refer
multitrigg
asthma
formerli
call
persist
asthma
nation
intern
guidelin
recommend
daili
inhal
corticosteroid
cornerston
therapi
children
multitrigg
asthma
schoolag
children
adult
recommend
base
solid
evid
deriv
sever
random
control
trial
metaanalys
randomis
trial
confirm
superior
placebo
leukotrien
receptor
antagonist
preschool
children
multitrigg
asthma
evid
support
efficaci
mainten
inhal
corticosteroid
less
abund
less
convinc
peak
trial
involv
children
age
year
high
risk
asthma
four
episod
prior
year
either
one
major
risk
factor
parent
histori
asthma
person
histori
atop
dermat
two
three
minor
risk
factor
allerg
rhiniti
eosinophilia
wheez
without
cold
enrol
children
posit
aeroallergen
skin
test
suggest
allerg
multitrigg
asthma
major
children
low
dose
daili
fluticason
two
year
associ
signific
reduct
episodefre
day
rescu
bronchodil
use
exacerb
requir
rescu
oral
corticosteroid
significantli
improv
lung
function
placebo
efficaci
daili
mainten
inhal
corticosteroid
improv
symptom
prevent
exacerb
patient
age
multitrigg
asthma
clearli
establish
preschoolag
children
viralinduc
asthma
daili
inhal
corticosteroid
shown
superior
placebo
studi
involv
children
viralinduc
wheez
minim
symptom
episod
group
differ
rescu
oral
corticosteroid
admiss
symptom
sever
durat
episod
treatment
low
dose
budesonid
ugday
vs
placebo
figur
admittedli
studi
small
underpow
identifi
signific
differ
import
outcom
episod
requir
rescu
oral
corticosteroid
interest
children
age
year
viralinduc
asthma
includ
children
symptom
exacerb
daili
montelukast
show
group
differ
rescu
oral
corticosteroid
appear
effect
placebo
reduc
frequenc
sever
exacerb
latter
studi
includ
children
interim
symptom
episod
unclear
whether
observ
benefit
primarili
appli
children
multitrigg
viralinduc
asthma
although
literatur
scarc
current
evid
support
efficaci
daili
mainten
corticosteroid
preschoolag
children
viralinduc
asthma
strategi
clearli
effect
children
multitrigg
asthma
sever
year
nation
intern
consensu
statement
recommend
dosedoubl
inhal
corticosteroid
home
manag
exacerb
children
adult
multitrigg
asthma
recent
recommend
withdrawn
view
lack
effect
report
sever
random
control
trial
inde
cochran
review
report
evid
superior
dosedoubl
dosequadrupl
inhal
corticosteroid
placebo
home
manag
exacerb
one
small
paediatr
trial
dosedoubl
contribut
data
review
figur
subgroup
analysi
perform
per
protocol
suggest
quadrupl
dose
inhal
corticosteroid
may
benefici
reduc
need
physicianiniti
rescu
oral
corticosteroid
adult
caution
advis
howev
interpret
subgroup
analys
overal
evid
would
suggest
patient
multitrigg
asthma
effect
strategi
prevent
reduc
sever
exacerb
remain
simpli
daili
intak
inhal
corticosteroid
contrast
preschoolag
children
viralinduc
asthma
symptom
exacerb
highdos
inhal
corticosteroid
ugday
budesonid
onset
upper
respiratori
tract
infect
appear
effect
inde
cochran
review
three
trial
show
nonsignific
trend
toward
reduct
rate
rescu
oral
corticosteroid
improv
symptom
parent
prefer
figur
efficaci
approach
recent
confirm
recent
trial
initi
highdos
fluticason
mgday
onset
exacerb
associ
reduct
need
rescu
oral
corticosteroid
reduct
marker
sever
durat
exacerb
clearli
effect
strategi
associ
small
signific
reduct
growth
term
altern
treatment
preempt
trial
suggest
modest
effect
intermitt
montelukast
placebo
parallelgroup
placebocontrol
trial
involv
children
age
year
age
physiciandiagnos
intermitt
asthma
episod
asymptomat
asthma
medic
intermitt
montelukast
associ
reduct
health
care
utilis
modest
reduct
symptom
school
parentwork
absente
group
differ
use
rescu
oral
corticosteroid
rescu
inhal
admittedli
substanti
proport
children
older
year
may
unrecognis
persist
asthma
avail
headtohead
comparison
studi
intermitt
budesonid
intermitt
montelukast
placebo
bachari
colleagu
suggest
import
group
differ
preschoolag
children
viralinduc
asthma
studi
compar
mg
twice
daili
nebul
budesonid
mg
montelukast
placebo
children
age
year
moder
sever
intermitt
wheez
associ
upper
respiratori
tract
infect
minor
symptom
episod
group
differ
episodefre
day
health
care
use
qualiti
life
growth
nonsignific
trend
toward
less
use
rescu
oral
steroid
children
treat
high
dose
budesonid
compar
montelukast
placebo
p
suggest
possibl
insuffici
power
updat
cochran
review
progress
aggreg
addit
trial
confirm
effect
highdos
inhal
corticosteroid
preschoolag
children
viralinduc
asthma
discord
respons
highdos
inhal
corticosteroid
preschoolag
children
viralinduc
asthma
stepup
therapi
children
adult
multitrigg
asthma
underlin
import
phenotypespecif
treatment
yet
phenotyp
treatment
degre
variabl
magnitud
respons
ic
ltra
preschoolag
children
whether
multitrigg
viralinduc
asthma
consid
flat
doserespons
curv
corticosteroid
good
respons
expect
lowdos
inhal
corticosteroid
children
multitrigg
asthma
face
poor
respons
trial
therapi
altern
drug
stepup
strategi
care
document
respons
advis
hand
possibl
quadrupl
doubl
daili
dose
inhal
steroid
may
effect
reduc
sever
exacerb
would
support
content
viral
infect
induc
certain
degre
corticoresist
frequent
asthma
trigger
evidencebas
manag
acut
asthma
includ
inhal
agonist
patient
system
usual
oral
corticosteroid
moder
sever
asthma
unsatisfactori
respons
inhal
agonist
repeat
dose
inhal
b
agonist
anticholinerg
sever
exacerb
latter
two
recommend
independ
reduc
admiss
rate
studi
combin
preschooland
schoolag
children
well
adult
treatment
oral
corticosteroid
far
effect
prevent
hospit
admiss
note
recommend
severityspecif
patient
mild
asthma
appear
benefit
oral
corticosteroid
delay
action
oral
corticosteroid
hour
spearhead
concept
golden
first
hour
treatment
support
earli
aggress
asthma
manag
explain
appar
ineffect
clinic
care
pathway
earli
time
corticosteroid
stress
appli
although
recommend
rel
similar
across
age
group
evid
preschoolag
children
weaker
due
underrepresent
relev
trial
figur
importantli
accumul
evid
suggest
heterogen
magnitud
respons
oral
corticosteroid
inde
children
adult
moder
sever
acut
asthma
respond
suffici
well
discharg
within
hour
intak
substanti
proport
admit
presum
delay
poorer
respons
oral
corticosteroid
moreov
larg
placebocontrol
random
control
trial
children
age
month
mildtomoder
viralinduc
wheez
oral
corticosteroid
superior
placebo
reduc
length
stay
hospit
improv
pediatr
respiratori
assess
measur
clinic
score
despit
adequ
power
critic
suggest
absenc
respons
oral
corticosteroid
may
due
larg
proport
children
bronchiol
asthma
document
children
mild
diseas
sever
requr
corticosteroid
insuffici
corticosteroid
dosag
mgkg
prednisolon
prolong
stay
hospit
perhap
support
sever
yet
studi
elicit
major
discomfort
regard
acut
asthma
manag
young
children
rais
possibl
preschoolag
andor
viral
trigger
may
respons
poor
appar
respons
similar
concern
could
rais
view
nonrespons
children
homeadminist
oral
corticosteroid
inde
cochran
review
aggreg
two
trial
test
parentiniti
oral
corticosteroid
vs
placebo
children
age
year
intermitt
wheez
ill
includ
asthma
viral
wheez
oral
corticosteroid
fail
reduc
hospit
admiss
unschedul
medic
review
symptom
score
bronchodil
use
day
lost
work
school
fact
subgroup
analysi
preschool
treat
prednisolon
paradox
experienc
higher
rate
unschedul
medic
visit
compar
receiv
placebo
although
preschool
age
perhap
viral
trigger
may
cite
causal
follow
hypothes
also
rais
explain
lack
efficaci
parentiniti
treatment
view
efficaci
physicianiniti
oral
corticosteroid
lower
sever
exacerb
manag
home
compar
lead
physician
visit
difficulti
parent
make
accur
assess
sever
need
oral
corticosteroid
treatment
child
although
trial
studi
design
confound
issu
rais
possibl
preschoolag
children
viralinduc
phenotyp
may
show
decreas
respons
oral
corticosteroid
dismiss
untangl
age
vs
trigger
prompt
us
examin
potenti
determin
respons
urti
usual
viral
origin
frequent
trigger
asthma
exacerb
children
age
rsv
parainfluenza
viru
rhinoviru
frequent
implic
children
two
year
old
picornaviru
coronaviru
influenza
usual
associ
asthma
older
children
adult
acut
asthma
viral
infect
associ
longer
hospit
admiss
increas
sputum
neutrophil
suggest
predominantli
neutrophil
airway
inflamm
may
respond
poorli
oral
corticosteroid
studi
children
age
month
infect
rhinoviru
show
fewer
relaps
treat
oral
prednison
compar
placebo
suggest
rhinoviru
impair
respons
corticosteroid
placebocontrol
trial
young
children
wheez
prednisolon
significantli
decreas
overal
time
discharg
howev
reduc
half
length
stay
children
infect
picornaviru
fourfold
children
enteroviru
suggest
respons
may
organismdepend
clearli
oral
corticosteroid
may
effect
patient
viral
infect
without
perhap
due
neutrophil
airway
inflamm
condit
associ
poor
respons
corticosteroid
moreov
respons
may
organismspecif
hypothesi
requir
care
document
aetiolog
futur
studi
adequ
power
trial
treatment
prednison
show
mark
blunt
respons
adult
smoker
improv
forc
expiratori
volum
second
ml
ci
neversmok
compar
signific
chang
ml
current
smoker
blunt
respons
inhal
corticosteroid
also
document
adult
smoker
random
control
trial
mechan
behind
lack
respons
known
one
certainli
point
smoke
direct
toxic
proinflammatori
action
interfer
transcript
gene
associ
corticosteroid
respons
inde
smoke
frequent
associ
airway
neutrophilia
paediatr
exposur
tobacco
smoke
associ
higher
incid
urti
preval
asthma
greater
sever
exacerb
howev
impact
therapeut
respons
document
children
asthma
trial
examin
fail
report
subgroup
analys
environment
tobacco
smoke
exposur
activ
smoke
yet
heavier
environment
tobacco
smoke
exposur
preschool
spend
time
home
schoolag
children
may
explain
poorer
respons
young
children
question
address
whether
smoke
adolesc
short
smoke
histori
children
environment
tobacco
exposur
would
respond
well
oral
corticosteroid
expos
addit
age
perceiv
asthma
phenotyp
alleg
trigger
tobacco
smoke
exposur
number
factor
could
possibl
modul
respons
oral
corticosteroid
includ
gender
race
environment
trigger
f
g
two
promis
mechanist
pathway
may
explain
variat
magnitud
respons
oral
corticosteroid
name
gene
polymorph
may
reveal
potenti
geneenviron
interact
type
airway
inflamm
increas
evid
inherit
gene
determinist
genotyp
rather
genotyp
encod
potenti
rang
phenotyp
develop
respons
varieti
environment
trigger
consequ
variat
gene
modul
respons
corticosteroid
may
predispos
peopl
environmentallyinduc
problem
smokeor
viralinduc
asthma
two
major
group
gene
interest
affect
suscept
asthma
specif
phenotyp
directli
interf
respons
corticosteroid
code
major
compon
pathway
involv
corticosteroid
action
tabl
first
group
key
polymorph
gene
identifi
divid
code
xenobiot
metabol
enzym
code
mediat
inflamm
immun
specif
one
demonstr
affect
lung
function
diseas
sever
interact
exposur
environment
tobacco
smoke
select
polymorph
affect
gene
function
toprank
singl
nucleotid
polymorph
number
associ
studi
polymorph
found
correl
diseas
sever
polymorph
play
role
develop
persist
asthma
phenotyp
childhood
polymorph
link
pathogenesi
asthma
lung
function
smoker
gene
confer
suscept
earlyonset
asthma
particularli
interact
earli
life
exposur
environment
tobacco
smoke
null
genotyp
associ
increas
risk
asthma
rapid
declin
lung
function
among
smoker
receptor
gene
found
contribut
occurr
wheez
among
children
expos
tobacco
smoke
utero
earli
childhood
second
group
gene
affect
corticosteroid
pathway
three
gene
shown
correl
respons
corticosteroid
associ
replic
sever
cohort
identifi
polymorph
summar
tabl
genotyp
strongli
consid
clinic
therapeut
studi
advanc
understand
heterogen
respons
corticosteroid
importantli
better
character
phenotyp
respond
poor
respond
clinician
increas
evid
eosinophil
asthma
respons
corticosteroid
noneosinophil
asthma
use
induc
sputum
three
distinct
inflammatori
cell
pattern
report
paediatr
exacerb
noneosinophil
eosinophil
eosinophil
eosinophil
combin
eosinophilicneutrophil
eosinophil
neutrophil
children
contrari
adult
find
criteria
paucigranular
inflamm
describ
acut
paediatr
athma
higher
proport
sputum
neutrophil
associ
smoke
viral
infect
noneosinophil
inflammatori
phenotyp
adult
associ
poor
respons
corticosteroid
contrast
sputum
eosinophil
eosinophil
cation
protein
increas
exposur
allergen
decreas
corticosteroid
treatment
suggest
good
respons
eosinophil
inflamm
corticosteroid
recogn
exacerb
children
adult
caus
viral
infect
rel
corticoresist
neutrophil
inflamm
associ
urti
would
explain
ineffect
dosedoubl
inhal
corticosteroid
potenti
effect
dosequadrupl
onset
exacerb
would
also
explain
efficaci
short
cours
highdos
fluticason
onset
urti
decreas
sever
durat
exacerb
preschoolag
children
care
select
viralinduc
asthma
phenotyp
find
support
prior
cochran
review
word
increas
evid
geneenvironment
interact
influenc
type
amount
airway
inflamm
turn
modul
respons
corticosteroid
children
asthma
ongo
cohort
studi
test
hypothesi
acut
paediatr
asthma
importantli
explor
clinic
characterist
promis
marker
poor
respons
mark
heterogen
respons
corticosteroid
observ
whether
inhal
corticosteroid
daili
control
therapi
preemptiv
therapi
inhal
oral
corticosteroid
onset
flareup
system
corticosteroid
emerg
manag
children
acut
asthma
consid
increas
evid
contrast
allerg
multitrigg
asthma
preschoolag
children
viralinduc
asthma
may
display
certain
degre
corticosteroid
resist
requir
higher
dose
corticosteroid
overcom
design
confound
issu
includ
mix
diagnos
heterogen
phenotyp
mild
sever
determin
respons
may
includ
age
trigger
tobacco
smoke
exposur
genet
makeup
mechanist
pathway
corticoresist
may
origin
interact
genet
environ
lead
noneosinophil
mix
eosinophilicneutrophil
inflamm
mainten
lowdos
inhal
corticosteroid
remain
cornerston
manag
multitrigg
asthma
age
show
evid
effect
children
viralinduc
asthma
trial
daili
montelukast
insuffici
control
episod
episod
highdos
inhal
corticosteroid
care
monitor
medic
use
growth
may
consid
viralinduc
asthma
phenotypespecif
treatment
children
asthma
focu
futur
research
endeavour
francin
ducharm
receiv
research
fund
travel
support
fee
speak
andor
consult
fee
glaxosmithklin
merck
frosst
inc
merck
canada
novarti
nycom
confirm
diagnosi
asthma
ascertain
phenotyp
young
children
viralinduc
asthma
nasal
hygien
inhal
mainstay
preemptiv
manag
episod
daili
prevent
control
medic
use
low
dose
inhal
corticosteroid
recommend
trial
montelukast
may
consid
although
shown
reduc
rescu
oral
corticosteroid
preemptiv
highdos
inhal
corticosteroid
could
consid
children
whose
episod
remain
poorli
control
episod
requir
rescu
oral
steroid
andor
admiss
preced
month
administ
care
monitor
medic
use
growth
preemptiv
oral
corticosteroid
proven
effect
multitrigg
asthma
daili
prevent
control
medic
use
low
dose
inhal
corticosteroid
cornerston
treatment
effect
mean
prevent
allevi
sever
episod
nasal
hygien
inhal
ad
need
episod
dosedoubl
inhal
corticosteroid
recommend
preemptiv
oral
corticosteroid
proven
effect
examin
whether
follow
factor
determin
respons
oral
inhal
corticosteroid
age
gender
race
asthma
phenotyp
asthma
trigger
presenc
etiolog
viral
respiratori
infect
tobacco
smoke
exposur
develop
clinic
tool
assist
correctli
identifi
phenotyp
key
determin
respons
confirm
type
amount
airway
inflamm
modul
respons
corticosteroid
children
asthma
identifi
genotyp
link
viralinduc
phenotyp
test
hypothesi
geneenvironment
interact
modul
respons
corticosteroid
children
asthma
conduct
intervent
trial
focus
specif
phenotyp
stratifi
phenotyp
explor
phenotypespecif
respons
therapi
